A review of the literature on the impact of renal cancer therapy on quality of life

Journal of Clinical Nursing

Volumn 18, Issue 20, 2009, Pages 2783-2800

  Bird, Joanne ^a,b   Hayter, Mark ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b WESTON PARK HOSPITAL   (United Kingdom)

Author keywords

Cancer; Nurses; Quality of life; Renal nursing; Systematic review

Indexed keywords

HUMAN; KIDNEY TUMOR; MULTIMODALITY CANCER THERAPY; NURSING; PATHOPHYSIOLOGY; QUALITY OF LIFE; REVIEW;

COMBINED MODALITY THERAPY; HUMANS; KIDNEY NEOPLASMS; QUALITY OF LIFE;

EID: 69949177424     PISSN: 09621067     EISSN: 13652702     Source Type: Journal    
DOI: 10.1111/j.1365-2702.2009.02875.x     Document Type: Review

References (40)

1. Aitchison M, Oliver RT Miles A (2004) The Effective Management of Renal Cell Carcinoma. Aesculapius Medical Press, London. T, Ruckdeshel JC, Riddle DL, Blanchard CG, Penner LA, Coovert MD Quinn G (2003) Communication and consumer decision making about cancer clinical trials. Patient Education & Counselling, 50, 39 42.
2. Allen N (2004) The epidemiology of renal cell carcinoma: rates and risk factors. In The Effective Management of Renal Cell Carcinoma (Aitchison, M. et al.). Aesculapius Medical Press, London, pp. 3 18.
3. Anastasiadis AG, Davis AR, Sawczuk IS Fleming M (2003) Quality of life aspects in kidney cancer patients: data from a national registry. Supportive Care in Cancer 11, 700 706.
4. Atkins M (2005) Management of advanced renal cancer. Kidney International 67, 2069 2082.
5. Atkins M, Regan M McDermott D (2004) Update on the role of interleukin 2 and other cytokines in the treatment of patients with stage IV renal carcinoma. Clinical Cancer Research 10 (Suppl 6342s 6346s.
6. Atzpodien J, Küchler T, Wandert T Reitz M (2003) Rapid deterioration in quality of life during interleukin-2 and alpha-interferon-based home therapy for renal cell carcinoma is associated with a good outcome. British Journal of Cancer 89, 50 54.
7. Bertetto O, Bracarda S, Tamburini M Cortesi E (2001) Quality of life studies and genito-urinary tumors, Annals of Oncology 12 (Suppl 3 S43 S48.
8. Bukowski R, Cella D, Gondek K Escudier B (2007) Effects of Sorafenib on symptoms and quality of life: results from a large randomized placebo-controlled study in renal cancer. American Journal of Clinical Oncology 30, 220 227.
9. Cella D, Yount S, Brucker P, Du H, Bukowski R, Vogelzang N Bro W (2007) Development and validation of a scale to measure disease-related symptoms of kidney cancer. Value in Health 10, 285 293.
10. Clark P, Schover LR, Uzzo RG Hafez KS (2001) Quality of life and psychological adaptation after surgical treatment for localized renal cell carcinoma: impact of the amount of remaining renal tissue. Urology 57, 252 256.
11. Cohen L, de Moor C, Parker PA Amato RJ (2002) Quality of life in patients with metastatic renal cell carcinoma participating in a phase I trial of an autologous tumor-derived vaccine. Urologic Oncology 7, 119 124.
12. Coppin C, Schrader AJ, Varga Z, Pfoertner S Goelden U (2006) Targeted therapy for advanced renal cell carcinoma (protocol). Cochrane Database of Systematic Reviews Issue 2. Art. No. CD006017 DOI : CD006017 (Citation as instructed).
13. De Moor C, Sterner J, Hall M, Warneke C, Gilani Z, Amato R Cohen L (2002) A pilot study of the effects of expressive writing on psychological and behavioural adjustment in patients enrolled in a phase II trial of vaccine therapy for metastatic renal cell carcinoma. Health Psychology 21, 615 619.
14. Dillenburg WV, Poulakis V, Skriapas K, de Vries R, Ferakis N, Witzsch U, Melekos M Becht E (2006) Retroperitoneoscopic versus open surgical radical nephrectomy for large renal cell carcinoma in clinical stage cT2 or cT3a: quality of life, pain and reconvalescence. European Urology 49, 314 322.
15. Duman M (2005) Producing Patient Information: How to Research, Develop and Produce Effective Resources. King's Fund, London.
16. Ficarra V, Righetti R, D'Amico A, Pilloni S, Balzarro M, Schiavone D, Malossini G Mobilio G (2000) General state of health and psychological well-being in patients after surgery for urological malignant neoplasms. Urologia Internationalis 65, 130 134.
17. Ficarra V, Novella G, Sarti S, Novara G, Galfana A, Cavelleri S Artibani W (2002) Psycho-social well-being and general health status after surgical treatment for localized renal cell carcinoma. International Urology and Nephrology 34, 441 446.
18. Harding G, Cella D, Robinson D, Mahadevia P, Clark J Revicki D (2007) Symptom burden among patients with Renal Cell Carcinoma (RCC): Content for a symptom index. Health and Quality of Life Outcomes 5 [online]. Available at: http://www.hqlo.com/content/5/1/34 (accessed July 14 2007).
19. Heinzer H, Mir TS, Huland E Huland H (1999) Subjective and objective prospective, long-term analysis of quality of life during inhaled Interleukin-2 immunotherapy. Journal of Clinical Oncology 17, 3612 3620.
20. Horrobin D (2003) Are large clinical trials in rapidly lethal diseases usually unethical? Lancet 361, 695 697.
21. Khan K, ter Riet G, Glanville J, Sowden A Kleijnen J (2001) Undertaking Systematic Reviews of Research on Effectiveness; CRD's Guidance for those Carrying Out or Commissioning Reviews. CRD Report No. 4, 2nd edn. NHS Centre for Reviews and Dissemination, University of York, York.
22. Lesage K, Joniau S, Fransis K Van Poppel H (2007) Comparison between open partial and radical nephrectomy for renal tumours: perioperative outcome and health-related quality of life. European Urology 51, 614 620.
23. Litwin M, Hays R, Fink A, Ganz P, Leake B Brook R (1997) Health related quality of life outcomes in patients treated for metastatic kidney cancer: a pilot study. Journal of Urology 157, 1608 1612.
24. Ljungberg B, Hanbury DC, Kuczyk MA, Merseburger AS, Mulders PFA, Patard J-J Sinescu IC (2007) Guidelines on Renal Cell Carcinoma. European Association of Urology. Available at: http://www.uroweb.org/fileadmin/user-upload/ Guidelines/08-Renal-Cell-Carcinoma-2007.pdf (accessed April 5 2007).
25. Medical Research Council (2007) RE04: Randomised controlled trial of IFN-α IL-2 and 5FU versus IFN-α alone in metastatic renal cell carcinoma[online]. Medical Research Council, London. Available at: http://www.ctu.mrc.ac.uk/studies/RE04.asp (accessed June 20 2007).
26. Mills M Sullivan K (1999) The importance of information giving for patients newly diagnosed with cancer: a review of the literature. Journal of Clinical Nursing 8, 631 642.
27. Motzer R, Michaelson D, Redman GB, Hudes GR, Wilding G, Figlin RA, Ginsberg MS, Kim ST, Baum CM, Di Primo SE, Li Z, Bello CL, Theuer CP, George DJ Rini BI (2006) Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. Journal of Clinical Oncology 24, 16 24.
28. Motzer R, Bolger G, Boston B, Carducci M, Fishman M, Hancock S, Hauke R, Hudes G, Jonasch E, Kantoff P, Kuzel T, Lange P, Levine E, Lugothetis C, Margolin K, Poher K, Redman B, Robertson C, Samlowski W Sheinfeld J (2007a) National Comprehensive Cancer Network Clinical Practice; Guidelines in Oncology V2.2007 [online]. National Comprehensive Cancer Network, Jenkintown. Available at http://www.nccn.org/professionals/physician-gls/PDF/kidney.pdf (accessed 5 April 2007).
29. Office for National Statistics (2005a) Cancer Statistics Registrations; Registrations of Cancer Diagnosed in 2003, England. HMSO, London.
30. Office for National Statistics (2005b) Cancer Incidence and Mortality in the United Kingdom 2001-03. [online] London, ONS. Available at: http://www.statistics.gov.uk/downloads/theme-health/UK-inc&mort-final.xls (accessed 20 May 2006).
31. Pace K, Dyer SJ, Stewart RJ, Honey RJ, Poulin EC, Schlachta CM Mamazza J (2003) Health-Related quality of life after laparoscopic and open nephrectomy. Surgical Endoscopy 17, 143 152. (Pubitemid 41512080)
32. Pannek J, Hallner D, Kugler J, Haupt G, Kruskemper M Senger TH (1997) Quality of life of patients with renal cell carcinoma or prostate cancer after radical surgery. International Urology & Nephrology 29, 637 643.
33. Poulakis V, Witzsch U, De Vries R, Moeckel M Brect E (2003) Quality of life after surgery for localised renal cell carcinoma: comparison between radical nephrectomy and nephron-sparing surgery. Urology 62, 814 820.
34. Quinn M, Wood H, Cooper N Rowan S (2005) Cancer Atlas of the United Kingdom and Ireland 1991-2000; Studies on Medical and Population Subjects No. 68. Palgrave Macmillan, Basingstoke.
35. Shinohara N, Harabayashi T, Sato S, Hoika T, Tsuchiya K Koyanagi T (2001) Impact of nephron-sparing surgery on quality of life in patients with localised renal cell carcinoma. European Urology 39, 114 119.
36. Stebbing J Gore M (2001) The current status of interferon-alpha treatment in advanced renal cancer. BJU International 87, 559 601.
37. Tannir N, Cohen L, Wang X, Thall P, Matthew PF, Jonasch E, Siefker-Radtke A, Pagliaro LC, Chaan S Logothetis C (2006) Improved tolerability and quality of life with maintained efficacy using twice-daily low-dose interferon-alpha-2b: results of randomized phase II trial of low-dose versus intermediate-dose interferon-alpha-2b in patients with metastatic renal cell carcinoma. Cancer 107, 2254 2261.
38. Taylor K (2002) Researching the experience of kidney cancer patients. European Journal of Cancer Care 11, 200 204.
39. Tilling K, Sterne J, Brookes S Peters T (2005) Features and designs of randomized controlled trials and non-randomized experimental designs. In Handbook of Health Research Methods: Investigation, Measurement and Analysis Bowling, A Ebrahim S eds). Open University Press, Maidenhead, pp. 85 97.
40. US Food and Drug Agency (2006) Treatment for Advanced Kidney Cancer. FDA Consumer Magazine March-April 2006. [online] FDA. Available at: http://www.fda.gov/fdac/departs/2006/206-upd.html (accessed May 20 2006).